The Journal of Experimental Medicine
VeriKine-HS Human IFN-Beta
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents
This Article
Right arrow Full Text
Right arrow Full Text (PDF, 459K)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Spatz, L.
Right arrow Articles by Diamond, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Spatz, L.
Right arrow Articles by Diamond, B.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?
© The Rockefeller University Press, 0022-1007/1997/4/1317/ $5.00
The Journal of Experimental Medicine, Volume 185, Number 7, April 7, 1997 1317-1326

Article

Light Chain Usage in Anti–double-stranded DNA B Cell Subsets: Role in Cell Fate Determination

Linda Spatz*, Vladimir Saenko{ddagger}, Andrey Iliev{ddagger}, Lori Jones{ddagger}, Larisa Geskin{ddagger}, and Betty Diamond*,{ddagger}

From the * Department of Medicine, and {ddagger} Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York 10461

Two major mechanisms for the regulation of autoreactive B cells that arise in the bone marrow are functional silencing (anergy) and deletion. Studies to date suggest that low avidity interactions between B cells and autoantigen lead to B cell silencing, whereas high avidity interactions lead to deletion. Anti–double stranded (ds) DNA antibodies represent a pathogenic autospecificity in Systemic Lupus Erythematosus (SLE). An understanding of their regulation is critical to an understanding of SLE. We now demonstrate in a transgenic model in which mice express the heavy chain of a potentially pathogenic anti-DNA antibody that antibody affinity for dsDNA does not alone determine the fate of anti-dsDNA B cells. B cells making antibodies with similar affinities for dsDNA are regulated differently, depending on light chain usage. A major implication of this observation is that dsDNA may not be the self antigen responsible for cell fate determinations of anti-dsDNA B cells. Light chain usage may determine antigenic crossreactivity, and cross-reactive antigens may regulate B cells that also bind dsDNA.

Address correspondence to Linda Spatz, Albert Einstein College of Medicine, Microbiology and Immunology, Forchheimer 405, Bronx, NY 10461.

This project is supported by National Institutes of Health grants AI40163 (L. Spatz) and AR42533 (B. Diamond) and grants from the New York Chapter of the Arthritis Foundation. Linda Spatz is a recipient of a Young Scholar Award granted by the New York Partnership in Arthritis Research of the Arthritis Foundation, New York Chapter.

1Abbreviations used in this paper: ds, double-stranded; FR1, framework 1; ss, single-stranded; V, variable region.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS